Windtree Therapeutics

Cardiovascular/critical-care therapeutics -- istaroxime program now operated via subsidiary Seismic Pharmaceuticals Operations LLC

WINT · OTC · United States

Share price · WINT

$0.00-0.02 (-99.00%) 3M

no price since 14 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when WINT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 31 Jul 2026+100.0%

    Nothing announced by WINT that day or the session before.

  2. 27 Jul 2026+100.0%

    Nothing announced by WINT that day or the session before.

  3. 24 Jul 2026-99.0%

    Nothing announced by WINT that day or the session before.

  4. 8 Jul 2026+100.0%

    Nothing announced by WINT that day or the session before.

  5. 2 Jul 2026+100.0%

    Nothing announced by WINT that day or the session before.

  6. 29 Jun 2026+100.0%

    Nothing announced by WINT that day or the session before.

  7. 18 Jun 2026+100.0%

    Nothing announced by WINT that day or the session before.

  8. 12 Jun 2026+100.0%

    Nothing announced by WINT that day or the session before.

  9. 9 Jun 2026+100.0%

    Nothing announced by WINT that day or the session before.

  10. 3 Jun 2026+100.0%

    Nothing announced by WINT that day or the session before.

Share of unusual movement by asset

For each asset, the share of WINT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—9%
Sessions with no dated event—91%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
rostafuroxinNo recent activity
Phase 2
Endogenous ouabain / mutant adducinSmall molecule
Hypertension
Resistant Hypertension with Adducin/Ouabain Polymorphisms

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (13)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3—$1.9M$0.2M$28M-$6.4M operating cash flowreport ↗
View 12 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2—$2.2M$0.3M$11M-$2.7M operating cash flowreport ↗
2025-Q1—$2.3M$1.2M$4.0M-$2.4M operating cash flowreport ↗
2024-Q3—$2.0M$2.3M$2.8M-$6.4M operating cash flowreport ↗
2024-Q2—$9.9M$1.8M$12M-$2.3M operating cash flowreport ↗
2024-Q1—$2.3M$2.5M—-$3.0M operating cash flowreport ↗
2023-Q3—$2.1M$7.4M$4.4M-$3.9M operating cash flowreport ↗
2023-Q2—$1.8M$11M$6.6M-$3.5M operating cash flowreport ↗
2023-Q1—$1.4M$4.2M$4.1M-$2.5M operating cash flowreport ↗
2022-Q3—$1.5M$8.4M$4.1M-$4.1M operating cash flowreport ↗
2022-Q2—$3.0M$11M$17M-$5.3M operating cash flowreport ↗
2022-Q1—$5.3M$16M$8.1M-$6.7M operating cash flowreport ↗
2021-Q3—$4.7M$25M$8.2M-$5.3M operating cash flowreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$16M$1.8M$0.5M-$15M operating cash flowreport ↗

Windtree Therapeutics reported no revenue for fiscal 2024, with revenue not disclosed for the year. R&D spend was $16.28M, up 95.2% YoY from $8.34M. Cash and equivalents were $1.78M, and the company reported a net loss of $1.79M, with a quarterly net burn of $1.79M.

The 10-K highlights substantial doubt about the company’s ability to continue as a going concern and notes continued dependence on lead candidate istaroxime. Key disclosed events include a reverse stock split in April 2024, an asset purchase from Varian Biopharmaceuticals, license agreements involving Philip Morris aerosolization technology and Lees Pharmaceutical, and multiple financing transactions including convertible notes, senior secured notes, and private placement activity.

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY—$8.3M$4.3M$5.1M-$13M operating cash flowreport ↗
2022-FY—$11M$6.2M$9.8M-$19M operating cash flowreport ↗
2021-FY—$18M$22M$17M-$24M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2024-10-08Fraser Craig · director, President and CEOOpen-market purchase5,431$0.91$5KForm 4
2024-07-22Fraser Craig · director, President and CEOAward / grant (derivative)19——Form 4
2024-07-22Simonson Steven · SVP, Chief Medical OfficerAward / grant (derivative)13——Form 4
2024-07-22Fraser Craig · director, President and CEOAward / grant (derivative)4,011——Form 4
2024-07-22Simonson Steven · SVP, Chief Medical OfficerAward / grant (derivative)2,674——Form 4
2023-09-27Fraser Craig · director, President and CEOOpen-market purchase2,500$1.02$3KForm 4
2023-09-26Fraser Craig · director, President and CEOOpen-market purchase2,500$0.90$2KForm 4
2023-08-23Geffken Daniel E. · directorAward / grant2,033——Form 4